Travere Therapeutics

TVTX

ATLANTA, GA (Globe Newswire – January 14, 2026) — Holzer & Holzer, LLC is investigating whether Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX) complied with federal securities laws. On January 13, 2026, Travere disclosed that the U.S. Food and Drug Administration has extended the review timeline of its supplemental New Drug Application for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis. Following this news, the price of the Company’s stock dropped.

If you purchased Travere stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/travere-therapeutics/ to discuss your legal rights.

 

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information
Submit Your Form

Submit Your Information

Name(Required)
Address
Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
 
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.